Table 3.
Expression of Cyclin D1 due to clinical, histological and epidemiological criteria in patients with laryngeal lesions (IA—impossible analysis).
| Cyclin D1 Median (IQR) | PLLs (n = 83) | PLLs→LC (n = 17) | LC (n = 101) |
|---|---|---|---|
| Age | |||
| <55 | 10 (5–20) | 30 (5–40) | 20 (5–35) |
| >55 | 10 (5–10) | 20.5 (12.5–35) | 20 (10–40) |
| p | 0.94 | 0.82 | 0.73 |
| Gender | |||
| Female | 10 (2–15) | 5 (5–5) | 10 (5–20) |
| Male | 10 (5–15) | 28 (12–40) | 20 (10–35) |
| p | 0.73 | 0.001 | 0.055 |
| Primary site | |||
| Epiglottic | 10 (7.5–15) | 26 (15–30) | 25 (10–35) |
| Glottic | 10 (5–15) | 22.5 (10–43) | 20 (10–35) |
| p | 0.23 | 0.84 | 0.43 |
| Tumor extension | |||
| T1, T2 | 40 (15–46) | 15 (10–30) | |
| T3, T4 | 20.5 (7.5–32.5) | 20 (10–35) | |
| p | 0.15 | 0.35 | |
| Nodal involvement | |||
| N0 | 22.5 (10–40) | 20 (10–35) | |
| N1, N2, N3 | 26 (5–30) | 22.5 (12.5–35) | |
| p | 0.53 | 0.68 | |
| TNM stage | |||
| I | 30.5 (15–48) | 10 (10–30) | |
| II | 40 (40–40) | 20 (5–40) | |
| III | 10 (5–30) | 20 (10–30) | |
| IV | 30 (26–60) | 28 (15–40) | |
| p | IA | 0.35 | |
| Histological grading | |||
| G1 | 22.5 (10–46) | 15 (10–35) | |
| G2 | 20.5 (5–40) | 20 (10–32.5) | |
| G3 | 30 (30–30) | 22.5 (10–40) | |
| p | IA | 0.82 | |
| Local recurrence | |||
| present | 40 (20–40) | 35 (20–40) | |
| absent | 20 (10–37.5) | 20 (10–35) | |
| p | IA | 0.07 | |
| Nodal recurrence | |||
| present | 15 (10–40) | 22.5 (10–30) | |
| absent | 30 (26–40) | 20 (10–40) | |
| p | IA | 0.59 |